#Nykaa Q3 2022 Concall Highlights 💅

Like & Retweet for better reach !

Financial highlights

1. Consolidated Revenue from Operations grew 24% QoQ and 36% YoY to ₹ 1098.4 Cr in Q3 FY22
2.Revenue from sale of products grew 24% QoQ
3. Income from Marketplace services grew 2% QoQ and 154% YoY in Q3 FY22.

4. Advertisement revenue grew 33% QoQ and 53% YoY in Q3 FY22,
EBITDA was ₹ 69 Cr in Q3 FY22 at a margin of 6.3% vs 3.3% in Q2 FY22.
5. PAT was ₹ 290 million in Q3 FY22 a -58%YoY decline. This was mainly due to higher marketing expense.
6. ₹ 430 cr cash balance in the books.
Business Highlights

1. Consolidated GMV grew 26% sequentially to ₹ 2043.5 Cr in Q3 FY22.
2. Beauty and Personal Care (BPC) GMV grew 29% QoQ and 32% YoY to ₹ 1533.3 Cr in Q3 FY22.
3. Fashion GMV grew 17% QoQ and 137% YoY to ₹ 510.2 Cr, contributing 25% to consolidated GMV in Q3 FY22 and grew 236% year to date FY22.

4. Q3 is usually a strong quarter for beauty .
5. Average Monthly Unique Visitors in BPC vertical grew 4% QoQ and 39% YoY to 22.0 million, and in Fashion vertical grew 1% QoQ and 120% YoY to 16.4 million in Q3 FY22.
Key BPC Business Highlights

1. In Q3 FY22, Nykaa Cosmetics launched a new format of quick drying nail enamel called Nykaa Insta Dry
2. Company also Introduced 100% Natural Hair Oils to increase market share in the Hair category and further penetrate their skincare offering with the 20% Vitamin C serum.
3. Company introduced multiple international brands like Sol de Janeiro, Elemis, 111Skin, Nudestix across premium and luxe categories.
4. Company has accelerated store expansion this quarter, with 12 new physical retail stores across the country including stores in Tier 2/3 cities such as Jodhpur, Rajkot, Trivandrum.

5. Their total operational physical store count was 96 as of December 31, 2021 in 45 cities.
6. Company expanded warehouse storage space by 1.35 lakh square feet during Q3 FY22.

7. Company received 19.7 million orders in 9M FY22 and 7.6 million orders in Q3FY22 with an AOV of ₹1,966 in Q3FY22.
8. GMV of BPC grew 29% QoQ to ₹1533.3 Cr in Q3 FY22.

Key Fashion Business Highlights

1. In Q3 FY22, Nykaa Fashion launched its first TV campaign For Nakhrewalis.
2. Nykaa Fashion launched a popular Scandinavian brand- NA-KD in India. NA-KD is one of Europe's top 20 fastest growing companies and a leading fashion brand.
3. Nykaa Fashion collaborated with designer Nikhil Thampi for its owned brand RSVP launched Masaba for Nykd, an elevated sleepwear collection created in collaboration with designer Masaba Gupta.
4. Fashion Business had 16 million Monthly Average Unique Visitors in Q3FY22.

5. Company received 1.4 million orders in Q3FY22 with an AOV of ₹3,590.

6. GMV OF Fashion business grew 17% QoQ ₹510.2 Cr in Q3FY22.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Value Educator

Value Educator Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ValueEducator

Feb 11
#SRF Q3 Concall Highlights 🧪🧪

Like & Retweet for better reach !

Operational Highlights

1. Revenues for the quarter stood at ₹3,345.9 as against ₹2146.4 Cr in Q3FY21, translating growth of 55.9% YoY

2. EBITDA margins stood at 25.7%
Revenue breakup

Chemical business-42.6%, Packaging films-38.1%, Technical textile- 16.1% and others-3.2%
Business Highlights

1. Launched new pharma intermediate during the quarter and successfully conducted campaigns for 2-3 upcoming products.

2. Achieved highest ever production in key products and are constantly enhancing capacity utilisation at newly commissioned facility
Read 16 tweets
Feb 11
#Aartiindustries Q3 concall highlights

Like & Retweet for better reach !

Operational Highlights

1. Revenues for the quarter stood at ₹2376 Cr, with a robust growth of 100.1% YoY

2. Both the Pharmaceuticals & Specialty Chemicals segment outperformed during the quarter
3. Revenue expansion during the quarter includes cost escalations passed on to the customers due to substantial increase in raw material prices as well as fuel and logistics costs
4. Accrual of termination fees in respect of the long-term contract of ₹631 crores resulting in higher revenues. As a result, EBITDA includes ₹611 Crs during the quarter.
Read 18 tweets
Feb 11
#SHKelkar Q3 2022 Concall Highlights

Like & Retweet for better reach !

Operational Highlights

1. Revenues from operations stood at Rs. 396.6 crore in Q3FY22 as against Rs. 375.4 crore in Q3FY21, higher by 5.6%
2. EBITDA margins remained stable on a sequential basis at 15.8% translating to EBITDA of 63.8 crore

3. Gross margins in 9M FY22 stood at 41.4%

4. Q3 FY22 revenues growth was driven on the back of rebound in consumer demand led by discretionary items and new client wins.
5. While the domestic core fragrance segment delivered healthy performance, sales in Southeast Asia region continued to be affected by the Covid surge and is yet to recover
Read 19 tweets
Feb 11
#AurobindoPharma Q3 FY22 concall highlights 💊💊

Like & retweet for better reach !

1. Revenues for the quarter stood at ₹6002 Cr (1% decline YoY).
2. EBITDA was at ₹1016 Cr (20% decline YoY) for the quarter. EBITDA margins for the quarter were 16.9%. PAT stood at ₹604.3 Cr (80% decline YoY).
3. Revenue from formulations was ₹4992 Cr (12% decline YoY).

4. Formulations contributed about 83% of total revenues. Revenue from the API business stood at ₹1010 Cr (48% growth YoY) and contributed about 17% of revenues.
Read 18 tweets
Feb 11
#HesterBiosciences Q3 FY22 concall highlights 🐓🐓

Like & Retweet for better reach !

1. Revenues are flat and profitability is down because of the high base effect.
2. Q3 and Q4 of FY21 were phenomenal quarters for the company because there was a major poultry disease outbreak which led to increased demand for vaccines.

3. They also have additional income every year from licensing fees which is not there in Q3 FY22.
4. They have been working on 3 vaccines - classical swine fever, lumpy skin disease and sheep pox vaccine. All these vaccines are in the final stages of quality testing and regulatory approval and they hope to launch them in Q1 FY23.
Read 14 tweets
Feb 11
#AlembicPharma Q3 FY22 concall highlights

Like & Retweet for better reach !

1. Revenues for the quarter stood at ₹1272 Cr (3% decline YoY).

2. EBITDA for the quarter was ₹269 Cr (33% decline YoY). EBITDA margin was at 21% for the quarter.
3. PAT stood at 176 Cr (40% decline YoY).

4. They believe the price erosion in the US business has normalized and they can grow with new launches from here on.
5. They have a couple of first-to-file launches coming up in FY23.

6. R&D expenditure for the quarter was at ₹154 Cr which is about 12% of sales. They have filed 6 ANDAs during the quarter.
Read 11 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

:(